IMI2 - Call 20

IMI2 - Call 20 was launched on 21 January 2020 with the following topics:

  • Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis
  • Innovations to accelerate vaccine development and manufacture
  • Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)
    This topic is part of the IMI AMR Accelerator programme
  • Tumour plasticity
  • Proton versus photon therapy for oesophageal cancer – a trimodality strategy
  • Handling of protein drug products and stability concerns<

More information on the topics can be found in IMI's press release and in the Call text. Additional information relevant to the UNITE4TB topic can also be found in the Questions and Answers document on the AMR Accelerator Programme. Other relevant documents can be found on the IMI2 Call documents page.

Projects

The projects resulting from IMI2 - Call 20 are:

  • HIPPOCRATES - Health initiatives in psoriasis and psoriatic arthritis consortium European states
    factsheet | website
  • Inno4Vac - Innovations to accelerate vaccine development and manufacture
    factsheet
  • PERSIST-SEQ - Building a reproducible single-cell experimental workflow to capture tumour drug persistence
    factsheet | website
  • PROTECT-trial - Proton versus photon therapy for esophageal cancer - a trimodality strategy
    factsheet | website
  • RealHOPE - Real world handling of protein drugs - exploration, evaluation and education
  • UNITE4TB - Academia and industry united innovation and treatment for tuberculosis
    factsheet | website

Call statistics

  • Proposals submitted: 27
  • Inadmissible & ineligible proposals: 2
  • Proposals recommended for funding: 6
  • Proposals not recommended for funding: 19

Reports